Aryabhatta Sadhu to Present Multivariable Predictors of Bleeding in Prophylactic Transfusion at ISBT 2025
Aryabhatta Sadhu, Senior Resident Doctor at AIIMS, shared on LinkedIn:
”From “more platelets” to “smarter transfusions.”
At International Society of Blood Transfusion (ISBT) 2025 (Perth), I’ll be presenting Poster BP061 — “Multivariable Predictors of Bleeding in Prophylactic Transfusion: Coagulopathy and Refractoriness Outweigh Platelet Concentrate Dosage.”
Our findings challenge the long-held “dose-response” paradigm in prophylactic transfusion.
Despite higher platelet increments with high-dose transfusions, bleeding outcomes remained unchanged.
Instead, coagulopathy (DIC) and refractoriness (spleen size, fever, chemo timing) emerged as the true drivers of bleeding risk.
This work pushes toward personalized, coagulation-integrated transfusion strategies—a necessary shift for safer, patient-centered care.
Poster: BP061, Exhibition hall, ground level, Perth convention and exhibition centre.
Venue: International Society of Blood Transfusion (ISBT) 2025, Perth, WA, Australia.
Colleagues and collaborators in transfusion medicine, hematology, and clinical research are welcome to connect for further discussions.”
Stay updated with Hemostasis Today.
-
Nov 27, 2025, 16:00Nathan Connell on WFH AI Summaries from the Global Forum
-
Nov 27, 2025, 15:49Piotr Czempik: Rethinking Coagulation in Acute Liver Dysfunction
-
Nov 27, 2025, 15:35Overwhelmed? A Leader’s Guide from Mark Crowther to Getting Back on Track
-
Nov 27, 2025, 15:10Wolfgang Miesbach’s Top 10 Picks for TTP and Thrombosis from ASH 2025
-
Nov 27, 2025, 14:24ICCBBA’s Executive Director Eoin McGrath Chairs a Dynamic Session on AI, Innovation and Informatics in Transfusion Medicine
-
Nov 27, 2025, 13:26Wolfgang Miesbach’s Top 10 Picks for Bleeding Disorders from ASH 2025
-
Nov 27, 2025, 11:19Priya Prasad Presents a Case of Severe Hypotensive Transfusion Reaction
-
Nov 27, 2025, 04:07Eugene Tang Presents Highlights from UK Stroke Forum 2025
-
Nov 27, 2025, 03:47Michael Makris: I Believe the Time Has Come to Consider Emicizumab Up Front in Persons with Acquired Hemophilia